Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
20.57
USD
|
-6.12%
|
|
+3.73%
|
-9.10%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
287.8
|
720.9
|
626.1
|
592.6
|
-
|
-
|
Enterprise Value (EV)
1 |
233.6
|
591.7
|
626.1
|
529.5
|
599.4
|
592.6
|
P/E ratio
|
-6.3
x
|
-14
x
|
-7.89
x
|
-6.39
x
|
-6.62
x
|
-7.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
157
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
157
x
|
EV / EBITDA
|
-
|
-11,128,828
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8.47
x
|
-15
x
|
-
|
-6.7
x
|
-6.93
x
|
-8.47
x
|
FCF Yield
|
-11.8%
|
-6.64%
|
-
|
-14.9%
|
-14.4%
|
-11.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
24,410
|
24,605
|
27,669
|
28,808
|
-
|
-
|
Reference price
2 |
11.79
|
29.30
|
22.63
|
20.57
|
20.57
|
20.57
|
Announcement Date
|
3/30/22
|
3/29/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3.767
|
EBITDA
|
-
|
-
|
-53.17
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-23.02
|
-53.24
|
-81.41
|
-99.76
|
-103.8
|
-110.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,924.84%
|
Earnings before Tax (EBT)
1 |
-
|
-22.96
|
-51.49
|
-75.46
|
-93.5
|
-98.55
|
-106.5
|
Net income
1 |
-9.611
|
-22.96
|
-51.51
|
-75.52
|
-94.76
|
-100.4
|
-106.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,826.95%
|
EPS
2 |
-40.32
|
-1.870
|
-2.100
|
-2.870
|
-3.217
|
-3.107
|
-2.868
|
Free Cash Flow
1 |
-
|
-27.58
|
-39.32
|
-
|
-79
|
-86.5
|
-70
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,858.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/6/21
|
3/30/22
|
3/29/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.268
|
-11.02
|
-12.22
|
-14.15
|
-15.85
|
-17.64
|
-20.34
|
-21.37
|
-22.07
|
-24.62
|
-24.21
|
-24.67
|
-24.18
|
-22.2
|
-22.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-8.22
|
-10.91
|
-11.99
|
-13.59
|
-15
|
-16.52
|
-19.02
|
-19.56
|
-20.36
|
-23.19
|
-22.1
|
-22.52
|
-21.99
|
-20.4
|
-21
|
Net income
1 |
-8.223
|
-10.91
|
-11.99
|
-13.59
|
-15.02
|
-16.52
|
-19.02
|
-19.56
|
-20.41
|
-23.19
|
-22.68
|
-23.12
|
-22.81
|
-20.4
|
-21
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0700
|
-0.4500
|
-0.4900
|
-0.5600
|
-0.6100
|
-0.6700
|
-0.7600
|
-0.7100
|
-0.7400
|
-0.8300
|
-0.7920
|
-0.8000
|
-0.7900
|
-0.6350
|
-0.6500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/16/22
|
8/15/22
|
11/14/22
|
3/29/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/25/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
6.79
|
-
|
Net Cash position
1 |
-
|
54.2
|
129
|
-
|
63.1
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-27.6
|
-39.3
|
-
|
-79
|
-86.5
|
-70
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.18
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/6/21
|
3/30/22
|
3/29/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
20.57
USD Average target price
44.67
USD Spread / Average Target +117.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -9.10% | 593M | | +33.63% | 50.93B | | -0.09% | 42.12B | | +49.62% | 42.05B | | -4.96% | 29.18B | | +11.18% | 26.02B | | -21.95% | 18.9B | | +8.61% | 13.21B | | +24.73% | 12.17B | | +28.31% | 12.16B |
Other Biotechnology & Medical Research
|